AI Terminal
Q-Linea
Declaration of Voting Results & Voting Rights Announcements • Jul 31, 2025
3100_rns_2025-07-31_e8d7390b-70d2-4194-88c9-4de2d38ef1e2.pdf
Declaration of Voting Results & Voting Rights Announcements
Open in ViewerOpens in native device viewer
New number of shares and votes in Q-linea AB (publ)
The number of shares and votes in Q-linea AB (publ) (the "Company") has changed during the month of July following the completion of the issue of equalization shares and the subsequent reverse share split (1:1000). The number of shares and votes in the Company amounts to 6,436,873 as of July 31, 2025.
As of 31 July 2025, the total number of shares in the Company amounts to 6,436,873 shares (previously 6,430,039,725 shares) with one vote each. All shares are ordinary shares. The share capital amounts to SEK 64,368,730 (previously 64,300,397.25). A reduction of the share capital by SEK 63,725,042.70, as resolved at the Annual General Meeting on 26 June 2025, is currently being processed by the Swedish Companies Registration Office. Q-linea AB holds 329 of its own shares as of 31 July 2025.
For more information, please contact:
Stuart Gander, President & CEO, Q-linea [email protected] +1 857 409 7463
Christer Samuelsson, CFO /IR, Q-linea AB [email protected] +46 (0) 70-600 15 20
About Q-linea
Q-linea's rapid AST system, ASTar®, accelerates and simplifies the time-sensitive workflows faced during the treatment of patients with bloodstream infections and sepsis. Hospitals use ASTar to vastly reduce the time to optimal antimicrobial therapies and ensure that patients receive the correct treatments sooner — when time matters most. We are helping to create sustainable healthcare, now and in the future, and safeguard the effectiveness of antibiotics for generations to come.
Q-linea is headquartered in Uppsala, Sweden and has regional offices in Italy and the USA, with partnerships worldwide.
ASTar Instrument and ASTar BC G- Consumable kit are CE-IVD marked and FDA 510(k) cleared. For more information, please visit www.qlinea.com
This information is information that Q-linea is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2025-07-31 08:30 CEST.